Expert Analysis

Treatment and Biomedical Prevention in Resource-Limited Settings

Source: CCO Official Conference Coverage of the 2008 International AIDS Conference

Treatment and Biomedical Prevention in Resource-Limited Settings


Faculty:

Richard E. Chaisson, MDElly Katabira, MDMauro Schechter, MD, PhD
  • Richard E. Chaisson, MD
  • Elly Katabira, MD
  • Mauro Schechter, MD, PhD

CME CREDIT INFORMATION

Release Date: 10/10/08

Expiration Date: 10/09/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status


Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize new data on the successes and challenges of antiretroviral scale-up programs in resource-limited settings
  • Recount new findings on mortality among patients receiving HAART in resource-limited settings
  • Discuss recent data on the use of immunologic and clinical criteria to estimate virologic failure in resource-limited settings
  • Describe recent insights on tuberculosis coinfection and prevention in HIV-infected patients, including data on complications associated with Bacillus Calmette-Guérin vaccination in HIV-infected children
  • Recall data on HIV prevention in males by circumcision

Topics covered include:

  • Project HEART: Role of Decentralization in Antiretroviral Scale-up Program in Sub-Saharan Africa
  • Survival Rates Observed With Scale-up of a National HIV Treatment Program in Botswana
  • Virologic Outcomes Observed in the Chinese National Antiretroviral Treatment Program
  • Early Mortality Reduced by Intensive Management of Patients With Low CD4+ Counts: A Kenyan Pilot Study
  • Mortality Among Patients Receiving HAART in the Caribbean and Central and South America
  • Use of Immunologic and Clinical Criteria Overestimates Virologic Failure: Haitian Cohort
  • Use of Immunologic and Clinical Criteria Permits Accumulation of Extensive Drug Resistance: Malawi Cohort
  • Variations in Outcome Indicators Among Major Donor-Supported Treatment Programs
  • Complications of Bacillus Calmette-Guérin Vaccination in HIV-Infected Children
  • Improved Survival Associated With HAART Use Following Tuberculosis Diagnosis
  • Circumcision Associated With Sustained Reduction in HIV Infection Risk


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.